Merus (MRUS) Stock Price, News & Analysis

Company Overview

Merus NV is a clinical-stage immuno-oncology company focused on the discovery and development of bispecific antibody therapeutics for the treatment of cancer. Utilizing its proprietary Biclonics® platform, Merus engineers fully human bispecific antibodies designed to engage immune cells and tumor targets simultaneously. The company’s research efforts are aimed at creating novel therapies with optimized potency, selectivity and safety profiles.

The Merus pipeline encompasses multiple Biclonics candidates in various stages of preclinical and clinical development. Key programs are being evaluated in solid tumors and hematological malignancies, with a focus on innovative mechanisms of action that harness T cell redirection, immune checkpoint modulation and co-stimulatory pathways. In addition to its internal development efforts, Merus collaborates with strategic partners to advance select programs and expand its therapeutic reach.

Headquartered in Utrecht, the Netherlands, Merus maintains operations in both Europe and the United States, supporting global clinical trials and regulatory activities. The company completed its initial public offering on the Nasdaq stock market in October 2018, and its research sites extend from the Dutch biotech hub to a dedicated U.S. presence in Boston’s ecosystem.

Merus is led by a management team with extensive experience in oncology drug development and commercialization. Under the leadership of Chief Executive Officer Ton Logtenberg, the company continues to advance its bispecific antibody platform, aiming to deliver transformative treatments for patients with unmet medical needs.

Key Stats

• Today's Range: $94.09 to $94.35
• 50-Day Range: $63.39 to $94.29
• 52-Week Range: $33.19 to $94.56
• Volume: 3.95 million shs
• Average Volume: 3.68 million shs
• Market Capitalization: $7.13 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $92.88
• Consensus Rating: Hold

Merus Stock Analysis - MarketRank™

Merus scored higher than 20% of companies evaluated by MarketBeat, and ranked 846th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Merus has received a consensus rating of Hold. The company's average rating score is 2.18, and is based on 4 buy ratings, 12 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Merus is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Merus has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Merus are expected to decrease in the coming year, from ($3.85) to ($4.17) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merus is -17.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merus is -17.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Merus has a P/B Ratio of 9.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.73% of the outstanding shares of Merus have been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Merus has recently decreased by 0.69%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Merus does not currently pay a dividend.

Dividend Growth

Merus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.73% of the outstanding shares of Merus have been sold short.

Short Interest Ratio / Days to Cover

Merus has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Merus has recently decreased by 0.69%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.24

News Sentiment

Merus has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 60 news articles for Merus this week, compared to 8 articles on an average week.

Search Interest

Only 7 people have searched for MRUS on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Merus to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Merus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,792,500.00 in company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Merus is held by insiders.

Percentage Held by Institutions

96.14% of the stock of Merus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MRUS Stock Analysis - Frequently Asked Questions

How have MRUS shares performed this year?

Merus' stock was trading at $42.05 at the beginning of 2025. Since then, MRUS shares have increased by 124.2% and is now trading at $94.29.

How were Merus' earnings last quarter?

Merus N.V. (NASDAQ:MRUS) issued its quarterly earnings data on Tuesday, August, 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.17) by $1.06. The biotechnology company earned $8.83 million during the quarter, compared to the consensus estimate of $9.77 million. Merus had a negative trailing twelve-month return on equity of 50.28% and a negative net margin of 685.64%.

When did Merus IPO?

Merus (MRUS) raised $64 million in an initial public offering on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

How do I buy shares of Merus?

Shares of MRUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Merus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Merus investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE), Jabil (JBL) and Disc Medicine (IRON).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 10/04/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MRUS
• CIK: 1651311
• Web: www.merus.nl
• Phone: (130) 253-8800
• Fax: N/A
• Employees: 37
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Merus: $92.88
• High Price Target: $110.00
• Low Price Target: $70.00
• Potential Upside/Downside: -1.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.18
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$215.33 million
• Net Margins: -685.64%
• Pretax Margin: -670.59%
• Return on Equity: -50.28%
• Return on Assets: -42.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.39
• Quick Ratio: 8.39

Sales & Book Value

• Annual Sales: $36.13 million
• Price / Sales: 197.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.46 per share
• Price / Book: 9.97

Miscellaneous

• Outstanding Shares: 75,630,000
• Free Float: 72,836,000
• Market Cap: $7.13 billion
• Optionable: Optionable
• Beta: 1.26